Core Insights - Exagen Inc. reported preliminary unaudited financial results for Q4 and the full year 2025, indicating strong revenue growth and operational progress [1][2]. Financial Performance - Total revenue for Q4 2025 is projected to be between $16 million and $17 million, while total revenue for the full year is expected to be between $66 million and $67 million [2]. - Year-over-year revenue growth for Q4 is estimated at 17% to 24%, and for the full year, growth is projected at 19% to 20% [2]. - The AVISE CTD test volume is expected to be between 136,000 and 137,000, with a trailing 12-month average selling price (ASP) of $441 to $445 [2]. - Year-end cash and cash equivalents are reported at $32 million, reflecting a $10 million increase from 2024 [4]. Operational Highlights - The company has made significant advancements in its commercial, scientific, and operational teams, leading to the launch of enhancements to the AVISE platform [2]. - The AVISE CTD ASP has expanded by at least $30 compared to 2024, and test volume has grown by at least 13,000, marking an 11% increase over the previous year [4]. Strategic Focus - Exagen aims to transform care for patients with autoimmune diseases through innovative testing solutions, enhancing decision-making and clinical outcomes [5]. - The company is committed to investing in innovation and advancing its strategy to improve the standard of care in autoimmune disease management [2].